Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
AZASAN |
| Manufacturer |
|
Salix Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immunosuppressant. |
| Generic Name |
|
Azathioprine 75mg, 100mg; scored tabs. |
| Indications |
|
To reduce signs/symptoms of active rheumatoid arthritis; may be used with aspirin, NSAIDs, and/or low dose corticosteroids. |
| Children |
|
Not recommended. |
| Adults |
|
Initially: 1mg/kg (50mg–100mg) daily in 1–2 divided doses; after 6–8 wks, if needed, may increase by 0.5mg/kg daily increments every 4-weeks. Max: 2.5mg/kg per day. Maintenance: use lowest effective dose. |
| Contraindications |
|
Pregnancy (Cat.D). Prior treatment with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan, or others) may increase risk of neoplasia. |
| Precautions |
|
Be fully familiar with product's toxicity before use. Risk of myelotoxicity with low or absent thiopurine S-methyl transferase (TPMT) activity. Monitor blood. Impaired renal function. Discontinue if ineffective after 12 weeks. Nursing mothers: not recommended. |
| Interactions |
|
Reduce dose to ⅓ or ¼ with allopurinol. TPMT enzyme inhibition with aminosalicylates (eg, sulphasalazine, mesalazine, olsalazine). Leukopenia with co-trimoxazole. Anemia, leukopenia with ACE Inhibitors. May antagonize warfarin. |
| Adverse Reactions |
|
Severe leukopenia and/or thrombocytopenia, macrocytic anemia, pancytopenia, severe bone marrow suppression, GI disturbances, secondary infections, mutagenic and carcinogenic potential, hepatotoxicity, rash. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
